TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02263976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat® A 4

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat® A 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine Chloride
Description: methacholine challenge test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methacholine Chloride
Description: methacholine challenge test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine Chloride
Description: methacholine challenge test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva
Study: NCT00755976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Study: NCT04450420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation based curriculum
Description: See arm/group description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard training
Description: See arm/group description
Study: NCT05028894

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01604512

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI perfusion and PET/CT scans
Description: The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
Study: NCT01364090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa 2b
Description: Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
Study: NCT03921008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: -Commercial supply

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -Patients may be treated with electrons, 3D conformal photon radiotherapy, intensity modulated photon radiotherapy (IMRT), proton radiation therapy, or a combination of these.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Within 1 week (prior to cycle 1 of paclitaxel preferred but not required), pre-radiation therapy (any time weeks 5-7 as long as radiation therapy has not started), post-radiation therapy (day of last fraction), 14 days post-radiation therapy, and within 2 weeks post-surgery
Study: NCT02050945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Study: NCT03553121

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking
Description: walking and not walking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking
Description: walking and not walking
Study: NCT03652337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlephEx
Description: Electronic lid margin debridement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual debridement
Description: Manual lid margin debridement
Study: NCT00505830

Intervention type: OTHER
Intervention: questionnaires
Description: Primary outcome:~Autism Spectrum Quotient (AQ)~Secondary outcome measure:~Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score
Study: NCT01364090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.
Study: NCT00957203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Oral istradefylline (KW-6002) 20 or 40 mg once daily
Study: NCT00928928

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open colectomy
Description: Open colectomy. Epidural anaesthesia used
Study: NCT05696184

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Slow and rapid intra-esophageal infusion
Description: A 3 mm outer diameter injection tube will be placed through the nose in a fashion that the injection port will be located 5-7cm above the manometrically determined upper border of lower esophageal sphincter (LES). With this arrangement gastroesophageal reflux events will be simulated by intra-esophageal injection of body temperature1/2 normal saline (its ionic nature helps impedance recording and identification of intra-esophageal distribution), 0.1 N HCl. Infused liquid will be colored green using food dye for ease of recognition of pharyngeal reflux. Esophageal clearance will be verified by the presence of an effective peristalsis and return of intra-esophageal impedance and pressure to baseline. Endoscopic views of pharynx will be watched carefully during infusions. At the first sign of reflux, perfusion will be stopped, and participants will be instructed to swallow to avoid any potential airway compromise.
Study: NCT02504580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam) by injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam) by injection.
Study: NCT05696184

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Slow and rapid intra-esophageal infusion
Description: A 3 mm outer diameter injection tube will be placed through the nose in a fashion that the injection port will be located 5-7cm above the manometrically determined upper border of lower esophageal sphincter (LES). With this arrangement gastroesophageal reflux events will be simulated by intra-esophageal injection of body temperature1/2 normal saline (its ionic nature helps impedance recording and identification of intra-esophageal distribution), 0.1 N HCl. Infused liquid will be colored green using food dye for ease of recognition of pharyngeal reflux. Esophageal clearance will be verified by the presence of an effective peristalsis and return of intra-esophageal impedance and pressure to baseline. Endoscopic views of pharynx will be watched carefully during infusions. At the first sign of reflux, perfusion will be stopped, and participants will be instructed to swallow to avoid any potential airway compromise.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Slow and rapid intra-esophageal infusion
Description: A 3 mm outer diameter injection tube will be placed through the nose in a fashion that the injection port will be located 5-7cm above the manometrically determined upper border of lower esophageal sphincter (LES). With this arrangement gastroesophageal reflux events will be simulated by intra-esophageal injection of body temperature1/2 normal saline (its ionic nature helps impedance recording and identification of intra-esophageal distribution), 0.1 N HCl. Infused liquid will be colored green using food dye for ease of recognition of pharyngeal reflux. Esophageal clearance will be verified by the presence of an effective peristalsis and return of intra-esophageal impedance and pressure to baseline. Endoscopic views of pharynx will be watched carefully during infusions. At the first sign of reflux, perfusion will be stopped, and participants will be instructed to swallow to avoid any potential airway compromise.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Slow and rapid intra-esophageal infusion
Description: A 3 mm outer diameter injection tube will be placed through the nose in a fashion that the injection port will be located 5-7cm above the manometrically determined upper border of lower esophageal sphincter (LES). With this arrangement gastroesophageal reflux events will be simulated by intra-esophageal injection of body temperature1/2 normal saline (its ionic nature helps impedance recording and identification of intra-esophageal distribution), 0.1 N HCl. Infused liquid will be colored green using food dye for ease of recognition of pharyngeal reflux. Esophageal clearance will be verified by the presence of an effective peristalsis and return of intra-esophageal impedance and pressure to baseline. Endoscopic views of pharynx will be watched carefully during infusions. At the first sign of reflux, perfusion will be stopped, and participants will be instructed to swallow to avoid any potential airway compromise.
Study: NCT01551043

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Study: NCT00505830

Intervention type: OTHER
Intervention: questionnaires
Description: Primary outcome:~Autism Spectrum Quotient (AQ)~Secondary outcome measure:~Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

Intervention type: OTHER
Intervention: questionnaires
Description: Primary outcome:~Autism Spectrum Quotient (AQ)~Secondary outcome measure:~Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score
Study: NCT02504580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam) by injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam) by injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam) by injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo by injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo by injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo by injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo by injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-002
Description: HTX-002, by injection or instillation (pooled).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-002
Description: HTX-002, by injection or instillation (pooled).
Study: NCT02504580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCI (Marcaine)
Description: Bupivacaine HCI (Marcaine) by injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCI (Marcaine)
Description: Bupivacaine HCI (Marcaine) by injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011A
Description: HTX-011A (bupivacaine/meloxicam) by injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011A
Description: HTX-011A (bupivacaine/meloxicam) by injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.
Study: NCT03312972

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR Brachytherapy
Description: HDR Brachytherapy implant, deliver 1 to 2 fractions, Up to 30 Gray (Gy) to target lesion
Study: NCT00157209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: After receiving single low dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until discontinuation from the study due to ECOG status of 4, participation in alternate trial, serious adverse event, or reasons that preclude assessment of clinical status in the opinion of the investigator, and in case of unavailability of study vaccine.
Study: NCT04406259

Intervention type: DRUG
Group type: OTHER
Intervention: Verapamil
Description: Patients in groupe A require verapamil initiation as a preventive treatment and patients in group B are patients already undergoing a verapamil treatment for their Cluster Headache.~The doses of verapamil are increased for the patients in group A, after a clinical examination an electrocardiogram, and a blood test.
Study: NCT02504580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-009
Description: HTX-009 by injection and instillation (combination).
Study: NCT03168178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Antibiotic Treatment
Description: Participants randomized to this intervention will receive standard antibiotic treatment.~The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Antibiotic Treatment
Description: Participant randomized to this arm of the study will not receive antibiotics. The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
Study: NCT00633529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2055
Description: 0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
Study: NCT03108560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sublobar resection
Description: Patients receive sublobar resection, which includes wedge resection and segmentectomy.
Study: NCT00974623

Intervention type: DEVICE
Intervention: Bone graft substitute, autograft or allograft
Description: spine fusion surgery utilizing any commercially available bone graft substitute(s), autograft or allograft
Study: NCT03108560

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lobectomy
Description: patients receive lobectomy
Study: NCT01564732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-LAGB
Description: The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plicated-LAGB
Description: At the time of LAGB placement, plication sutures can be placed along the body \& greater curvature of the stomach to tighten and cinch up the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss.
Study: NCT01052506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033
Description: Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
Study: NCT03190434

Intervention type: DEVICE
Intervention: AL-SENSE
Description: The AL-SENSE reacts differently when in contact with amniotic fluid than it does with urine. The indicator changes color to blue-green and fades back to yellow in case of urine and changes to stable blue-green in case of amniotic fluid.
Study: NCT00847886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX3305
Description: Daily oral intake of LX3305 for 14 days.
Study: NCT02414100

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study: NCT00772031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol LA
Description: Propranolol LA up to 240 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate
Description: Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topiramate
Description: Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study: NCT02040415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-1030(eperisone HCl) 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myonal Tab.(eperisone HCl) 50mg
Study: NCT00847886

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX3305 Placebo
Description: Matching placebo dosing with daily oral intake for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Once weekly stable-dose methotrexate.
Study: NCT00928928

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic colectomy
Description: Laparoscopic colectomy. Epidural anaesthesia used
Study: NCT03521986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subxiphoid uniportal VATS
Description: Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
Study: NCT00847886

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Once weekly stable-dose methotrexate.
Study: NCT00811681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: administered orally once a day after the first visit and for a total of 2 years. Initially, Pioglitazone will be started at 15mg /day. Dosage will then increase by 15mg /d/ week up to the maximal dose of 45mg /day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo administered orally once a day after the first visit and for a total of 2 years.
Study: NCT01110369

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: Protein drink twice a day during 6 months.
Study: NCT02040415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo drug of DW-1030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo drug of Myonal Tab.
Study: NCT03935074

Intervention type: DRUG
Intervention: intra-arterial administration of melphalan

Intervention type: DRUG
Intervention: intra-arterial administration of melphalan
Study: NCT01874379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'M'-Technique®
Description: 'M'-Technique is a series of gentle stroking movements performed in a set sequence, with a set pressure of 3 on a scale of 0-10.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Diane L. Tusek's Guided Imagery for Pre-Procedure/Surgery™ will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Normal Procedures, no complementary medicine intervention.
Study: NCT03521986

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal uniportal VATS
Description: The surgical procedures followed principles of pulmonary resections
Study: NCT02972216

Intervention type: DRUG
Intervention: Nolbaxol

Intervention type: DRUG
Intervention: Taxotere
Study: NCT01977066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Six months supervised resistance training
Description: progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Six months home-based exercise training
Description: Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery.
Study: NCT04057586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonintubated
Description: During surgery, patient is deeply sedated and respiration is maintained by spontaneous breath under the nasal high flow oxygen support.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubated
Description: During surgery, patient received standard general anesthesia and respiration is maintained by using mechanical ventilation.
Study: NCT03029793

Intervention type: OTHER
Intervention: Biomarkers Testing
Description: CRT resistance biomarkers will be detected before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
Study: NCT01110369

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance exercise training
Description: Resistance exercise training twice per week during 6 months.
Study: NCT02972216

Intervention type: DRUG
Intervention: cisplatin

Intervention type: DRUG
Intervention: cisplatin
Study: NCT01110369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Resistance exercise training twice per week during 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Placebo drink twice a day during 6 months.